Dr. Jorge S. Reis-Filho leads a cross-therapeutic team of oncology and biopharma AI across AstraZeneca, primarily focusing on the development and deployment of multimodal foundation models, advanced data science approaches, and agentic AI frameworks to drive innovation throughout AstraZeneca’s pipeline and portfolio. Through the integration of rigorously validated AI-driven approaches across R&D, AstraZeneca aims to accelerate drug discovery and transform the future of healthcare by unlocking the power of what science can do for people, society and the planet. Dr. Reis-Filho earned a joint MD from the University of Porto, Portugal, and the Universidade Federal do Paraná, Brazil; completed histopathology training at the University of Porto; and obtained a PhD in breast cancer molecular pathology from the Institute of Cancer Research and the Royal Marsden Hospital in London, where he rose to Team Leader and subsequently Professor and Chair of Molecular Pathology. In 2012, he joined Memorial Sloan Kettering Cancer Center in New York, becoming Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program in 2016. Author of more than 700 peer-reviewed papers, Dr. Reis-Filho has defined molecular taxonomies for rare tumours, created a predictive classification of breast cancer, elucidated the causes and consequences of intra-tumour genetic heterogeneity, and pioneered technologies ranging from single-cell DNA sequencing of archival tissue to FDA-cleared computational pathology diagnostics. His contributions to the field have been recognised by multiple awards, including the USCAP Ramzi Cotran Young Investigator Award (2010), the CRUK Future Leaders Prize (2010), the Goudie Medal and Lectureship (2023), the BCRF Larry Norton Award (2023), and the MSKCC William Gerald Award (2024). He is also the youngest individual ever elected Fellow of the Royal College of Pathologists by published works. Prior to joining AstraZeneca, Dr. Reis-Filho consulted for Goldman Sachs Merchant Banking and Bain Capital, in addition to serving on the boards of directors and scientific advisory boards for several biotechnology companies, guiding strategy across precision medicine and artificial intelligence.